Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Epstein-Barr Virus | Review

Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer

Authors: Ramon Yarza, Mateo Bover, Maria Teresa Agulló-Ortuño, Lara Carmen Iglesias-Docampo

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Nasopharyngeal carcinoma (NPC) represents a molecularly paradigmatic tumor given the complex diversity of environmental as well as host dependent factors that are closely implicated in tissue transformation and carcinogenesis. Epstein Barr Virus (EBV) plays a key role in tissue invasion, hyperplasia and malignant transformation. Therefore, EBV related oncoviral proteins such as Latent Membrane Protein family (LMP1, LMP2), Epstein Barr Nuclear Antigen 1 (EBNA1) and EBV related glycoprotein B (gB) are responsible for inducing intracellular signalling aberrations leading to sustained proliferation and further acquisition of NPC related invasive nature and metastatic potential.

Dysregulation of proteasome signaling seems to be centrally implicated in oncoviral protein stabilization as well as in modulating tumor microenvironment. Different studies in vitro and in vivo suggest a potential role of proteasome inhibitors in the therapeutic setting of NPC. Furthermore, alterations affecting proteasome signalling in NPC have been associated to tumor growth and invasion, distant metastasis, immune exclusion and resistance as well as to clinical poor prognosis. So on, recent studies have shown the efficacy of immunotherapy as a suitable therapeutic approach to NPC. Nevertheless, novel strategies seem to look for combinatorial regimens aiming to potentiate immune recognition as well as to restore both primary and acquired immune resistance.

In this work, our goal is to thoroughly review the molecular implications of proteasome dysregulation in the molecular pathogenesis of NPC, together with their direct relationship with EBV related oncoviral proteins and their role in promoting immune evasion and resistance. We also aim to hypothesize about the feasibility of the use of proteasome inhibitors as part of immunotherapy-including combinatorial regimens for their potential role in reversing immune resistance and favouring tumor recognition and eventual tumor death.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Nakanishi Y, Wakisaka N, Kondo S, Endo K, Sugimoto H, Hatano M, et al. Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma. Cancer Metastasis Rev. 2017;36(3):435–47. https://doi.org/10.1007/s10555-017-9693-x.CrossRefPubMedPubMedCentral

Bakkalci D, Jia Y, Winter JR, Lewis JE, Taylor GS, Stagg HR. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence. J Glob Health. 2020;10(1):10405. https://doi.org/10.7189/jogh.10.010405.CrossRef

Bei J-X, Li Y, Jia W-H, Feng BJ, Zhou G, Chen LZ, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010;42(7):599–603. https://doi.org/10.1038/ng.601.CrossRefPubMed

Natasya Naili MN, Hasnita CH, Shamim AK, Hasnan J, Fauziah MI, Narazah MY, et al. Chromosomal alterations in Malaysian patients with nasopharyngeal carcinoma analyzed by comparative genomic hybridization. Cancer Genet Cytogenet. 2010;203(2):309–12. https://doi.org/10.1016/j.cancergencyto.2010.07.136.CrossRefPubMed

Busson P, Keryer C, Ooka T, Corbex M. EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol. 2004;12(8):356–60. https://doi.org/10.1016/j.tim.2004.06.005.CrossRefPubMed

Chang ET, Adami H-O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol biomarkers Prev a Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol. 2006;15(10):1765–77. https://doi.org/10.1158/1055-9965.EPI-06-0353.CrossRef

Feng B-J, Jalbout M, Ben AW, et al. Dietary risk factors for nasopharyngeal carcinoma in Maghrebian countries. Int J Cancer. 2007;121(7):1550–5. https://doi.org/10.1002/ijc.22813.CrossRefPubMed

Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VMY, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014;50(5):330–8. https://doi.org/10.1016/j.oraloncology.2014.02.006.CrossRefPubMed

10.

Tang KF, Tan SY, Chan SH, Chong SM, Loh KS, Tan LKS, et al. A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumor infiltration by T lymphocytes and macrophages. Hum Pathol. 2001;32(1):42–9. https://doi.org/10.1053/hupa.2001.20886.CrossRefPubMed

11.

Chan ATC. Nasopharyngeal carcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2010;21(Suppl 7):vii308–12. https://doi.org/10.1093/annonc/mdq277.CrossRef

12.

Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645–55. https://doi.org/10.1016/S1470-2045(15)70126-9.CrossRefPubMed

13.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, et al. NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Cancer Netw. 2018;16(5):479–90. https://doi.org/10.6004/jnccn.2018.0026.CrossRef

14.

Iglesias Docampo LC, Arrazubi Arrula V, Baste Rotllan N, Carral Maseda A, Cirauqui Cirauqui B, Escobar Y, et al. SEOM clinical guidelines for the treatment of head and neck cancer (2017). Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex. 2018;20(1):75–83. https://doi.org/10.1007/s12094-017-1776-1.CrossRef

15.

Chen Y, Sun Y, Liang S-B, Zong JF, Li WF, Chen M, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of C. Cancer. 2013;119(12):2230–8. https://doi.org/10.1002/cncr.28049.CrossRefPubMed

16.

Meng D-F, Sun R, Peng L-X, Huang YS, Yang Q, Luo DH, et al. A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. J Cancer. 2018;9(1):92–9. https://doi.org/10.7150/jca.21357.CrossRefPubMedPubMedCentral

17.

Fournier B, Boutboul D, Bruneau J, et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. J Exp Med. 2020;217(11). https://doi.org/10.1084/jem.20192262.

18.

Liu W, Li H, Sheng H, Liu X, Chi P, Wang X, et al. A randomized controlled trial on evaluation of plasma Epstein-Barr virus biomarker for early diagnosis in patients with nasopharyngeal carcinoma. Adv Ther. 2020;37(10):4280–90. https://doi.org/10.1007/s12325-020-01461-4.CrossRefPubMed

19.

Lee VH-F, Kwong DL-W, Leung T-W, Choi CW, O'Sullivan B, Lam KO, et al. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer. 2019;144(7):1713–22. https://doi.org/10.1002/ijc.31856.CrossRefPubMed

20.

Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4(10):757–68. https://doi.org/10.1038/nrc1452.CrossRefPubMed

21.

Fitzsimmons L, Kelly GL. EBV and apoptosis: the viral master regulator of cell fate? Viruses. 2017;9(11). https://doi.org/10.3390/v9110339.

22.

Zhang H-J, Tian J, Qi X-K, Xiang T, He GP, Zhang H, et al. Epstein-Barr virus activates F-box protein FBXO2 to limit viral infectivity by targeting glycoprotein B for degradation. PLoS Pathog. 2018;14(7):e1007208. https://doi.org/10.1371/journal.ppat.1007208.CrossRefPubMedPubMedCentral

23.

Hutt-Fletcher LM. The Long and complicated relationship between epstein-barr virus and epithelial cells. J Virol. 2017;91(1). https://doi.org/10.1128/JVI.01677-16.

24.

Liu T-B, Zheng Z-H, Pan J, Pan L-L, Chen L-H. Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis. Clin Invest Med. 2017;40(1):E1–E12. https://doi.org/10.25011/cim.v40i1.28049.CrossRefPubMed

25.

Eliopoulos AG, Caamano JH, Flavell J, Reynolds GM, Murray PG, Poyet JL, et al. Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway. Oncogene. 2003;22(48):7557–69. https://doi.org/10.1038/sj.onc.1207120.CrossRefPubMed

26.

Murata T, Tsurumi T. Switching of EBV cycles between latent and lytic states. Rev Med Virol. 2014;24(3):142–53. https://doi.org/10.1002/rmv.1780.CrossRefPubMed

27.

Hui KF, Yiu SPT, Tam KP, Chiang AKS. Viral-targeted strategies against EBV-associated lymphoproliferative diseases. Front Oncol. 2019;9:81. https://doi.org/10.3389/fonc.2019.00081.CrossRefPubMedPubMedCentral

28.

Hu L, Lin Z, Wu Y, Dong J, Zhao B, Cheng Y, et al. Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing. Front Med. 2016;10(1):61–75. https://doi.org/10.1007/s11684-016-0436-0.CrossRefPubMed

29.

Choi SJ, Jung SW, Huh S, Cho H, Kang H. Phylogenetic comparison of Epstein-Barr virus genomes. J Microbiol. 2018;56(8):525–33. https://doi.org/10.1007/s12275-018-8039-x.CrossRefPubMed

30.

Verhoeven RJA, Tong S, Mok BW-Y, Liu J, He S, Zong J, et al. Epstein-Barr virus BART long non-coding RNAs function as epigenetic modulators in nasopharyngeal carcinoma. Front Oncol. 2019;9:1120. https://doi.org/10.3389/fonc.2019.01120.CrossRefPubMedPubMedCentral

31.

Lee J, Kosowicz JG, Hayward SD, et al. Pharmacologic activation of lytic epstein-barr virus gene expression without virion production. J Virol. 2019;93(20). https://doi.org/10.1128/JVI.00998-19.

32.

Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao GSW, Chiang AKS. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. Int J Cancer. 2012;131(8):1930–40. https://doi.org/10.1002/ijc.27439.CrossRefPubMed

33.

Bristol JA, Djavadian R, Albright ER, Coleman CB, Ohashi M, Hayes M, et al. A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection. PLoS Pathog. 2018;14(7):e1007179. https://doi.org/10.1371/journal.ppat.1007179.CrossRefPubMedPubMedCentral

34.

Hicke L. A new ticket for entry into budding vesicles-ubiquitin. Cell. 2001;106(5):527–30. https://doi.org/10.1016/s0092-8674(01)00485-8.CrossRefPubMed

35.

Celebi G, Kesim H, Ozer E, Kutlu O. The effect of dysfunctional ubiquitin enzymes in the pathogenesis of most common diseases. Int J Mol Sci. 2020;21(17). https://doi.org/10.3390/ijms21176335.

36.

Li L, Li Z, Zhou S, Xiao L, Guo L, Tao Y, et al. Ubiquitination of MDM2 modulated by Epstein-Barr virus encoded latent membrane protein 1. Virus Res. 2007;130(1–2):275–80. https://doi.org/10.1016/j.virusres.2007.05.013.CrossRefPubMed

37.

Hui KF, Tam KP, Chiang AKS. therapeutic strategies against epstein-barr virus-associated cancers using proteasome inhibitors. Viruses. 2017;9(11). https://doi.org/10.3390/v9110352.

38.

Hau PM, Tsang CM, Yip YL, Huen MSY, Tsao SW. Id1 interacts and stabilizes the Epstein-Barr virus latent membrane protein 1 (LMP1) in nasopharyngeal epithelial cells. PLoS One. 2011;6(6):e21176. https://doi.org/10.1371/journal.pone.0021176.CrossRefPubMedPubMedCentral

39.

Gainullin MR, Zhukov IY, Zhou X, Mo Y, Astakhova L, Ernberg I, et al. Degradation of cofilin is regulated by Cbl, AIP4 and Syk resulting in increased migration of LMP2A positive nasopharyngeal carcinoma cells. Sci Rep. 2017;7(1):9012. https://doi.org/10.1038/s41598-017-09540-3.CrossRefPubMedPubMedCentral

40.

Zhou H, Liu Y, Wang C, Liu L, Wang H, Zhang Y, et al. Triptolide inhibits Epstein-Barr nuclear antigen 1 expression by increasing sensitivity of mitochondria apoptosis of nasopharyngeal carcinoma cells. J Exp Clin Cancer Res. 2018;37(1):192. https://doi.org/10.1186/s13046-018-0865-5.CrossRefPubMedPubMedCentral

41.

Meng D-F, Sun R, Liu G-Y, Peng LX, Zheng LS, Xie P, et al. S100A14 suppresses metastasis of nasopharyngeal carcinoma by inhibition of NF-kB signaling through degradation of IRAK1. Oncogene. 2020;39(30):5307–22. https://doi.org/10.1038/s41388-020-1363-8.CrossRefPubMed

42.

Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, et al. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Res. 2012;72(7):1890–900. https://doi.org/10.1158/0008-5472.CAN-11-3472.CrossRefPubMedPubMedCentral

43.

Liu L, Yang J, Ji W, Wang C. Curcumin inhibits proliferation of Epstein-Barr virus-associated human nasopharyngeal carcinoma cells by inhibiting EBV nuclear antigen 1 expression. Biomed Res Int. 2019;2019:8592921–10. https://doi.org/10.1155/2019/8592921.CrossRefPubMedPubMedCentral

44.

Jiang G-M, Wang H-S, Du J, et al. Bortezomib relieves immune tolerance in nasopharyngeal carcinoma via STAT1 suppression and Indoleamine 2,3-dioxygenase downregulation. Cancer Immunol Res. 2017;5(1):42–51. https://doi.org/10.1158/2326-6066.CIR-16-0102.CrossRefPubMed

45.

Hui KF, Lam BHW, Ho DN, Tsao SW, Chiang AKS. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Mol Cancer Ther. 2013;12(5):747–58. https://doi.org/10.1158/1535-7163.MCT-12-0811.CrossRefPubMed

46.

Xu C, Sun L, Liu W, Duan Z. Latent membrane protein 1 of Epstein-Barr virus promotes RIG-I degradation mediated by proteasome pathway. Front Immunol. 2018;9:1446. https://doi.org/10.3389/fimmu.2018.01446.CrossRefPubMedPubMedCentral

47.

Tsao SW, Tramoutanis G, Dawson CW, Lo AKF, Huang DP. The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12(6):473–87. https://doi.org/10.1016/s1044579x02000901.CrossRefPubMed

48.

Chen H, Hutt-Fletcher L, Cao L, Hayward SD. A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J Virol. 2003;77(7):4139–48. https://doi.org/10.1128/jvi.77.7.4139-4148.2003.CrossRefPubMedPubMedCentral

49.

Johansson P, Jansson A, Rüetschi U, Rymo L. The p38 signaling pathway upregulates expression of the Epstein-Barr virus LMP1 oncogene. J Virol. 2010;84(6):2787–97. https://doi.org/10.1128/JVI.01052-09.CrossRefPubMedPubMedCentral

50.

Goormachtigh G, Ouk T-S, Mougel A, et al. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways. J Virol. 2006;80(15):7382–93. https://doi.org/10.1128/JVI.02052-05.CrossRefPubMedPubMedCentral

51.

Demetriades C, Mosialos G. The LMP1 promoter can be transactivated directly by NF-kappaB. J Virol. 2009;83(10):5269–77. https://doi.org/10.1128/JVI.00097-09.CrossRefPubMedPubMedCentral

52.

Johansson P, Jansson A, Rüetschi U, Rymo L. Nuclear factor-kappaB binds to the Epstein-Barr virus LMP1 promoter and upregulates its expression. J Virol. 2009;83(3):1393–401. https://doi.org/10.1128/JVI.01637-08.CrossRefPubMed

53.

Lo AKF, To KF, Lo KW, et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A. 2007;104(41):16164–9. https://doi.org/10.1073/pnas.0702896104.CrossRefPubMedPubMedCentral

54.

Aviel S, Winberg G, Massucci M, Ciechanover A. Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue. J Biol Chem. 2000;275(31):23491–9. https://doi.org/10.1074/jbc.M002052200.CrossRefPubMed

55.

Deng L, Yang J, Zhao XR, et al. Cells in G2/M phase increased in human nasopharyngeal carcinoma cell line by EBV-LMP1 through activation of NF-kappaB and AP-1. Cell Res. 2003;13(3):187–94. https://doi.org/10.1038/sj.cr.7290163.CrossRefPubMed

56.

Li YY, Chung GTY, Lui VWY, To KF, Ma BBY, Chow C, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat Commun. 2017;8(1):14121. https://doi.org/10.1038/ncomms14121.CrossRefPubMedPubMedCentral

57.

Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296–9. https://doi.org/10.1038/387296a0.CrossRefPubMed

58.

Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299–303. https://doi.org/10.1038/387299a0.CrossRefPubMed

59.

Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol. 2012;22(2):144–53. https://doi.org/10.1016/j.semcancer.2012.01.004.CrossRefPubMed

60.

Zhou X, Matskova L, Rathje L-SZ, Xiao X, Gish G, Werner M, et al. SYK interaction with ITGβ4 suppressed by Epstein-Barr virus LMP2A modulates migration and invasion of nasopharyngeal carcinoma cells. Oncogene. 2015;34(34):4491–9. https://doi.org/10.1038/onc.2014.380.CrossRefPubMed

61.

Yoo Y, Ho HJ, Wang C, Guan J-L. Tyrosine phosphorylation of cofilin at Y68 by v-Src leads to its degradation through ubiquitin-proteasome pathway. Oncogene. 2010;29(2):263–72. https://doi.org/10.1038/onc.2009.319.CrossRefPubMed

62.

Nanbo A, Sugden A, Sugden B. The coupling of synthesis and partitioning of EBV’s plasmid replicon is revealed in live cells. EMBO J. 2007;26(19):4252–62. https://doi.org/10.1038/sj.emboj.7601853.CrossRefPubMedPubMedCentral

63.

Chen H, Ma J, Sunkel B, Luo A, Ding F, Li Y, et al. S100A14: novel modulator of terminal differentiation in esophageal cancer. Mol Cancer Res. 2013;11(12):1542–53. https://doi.org/10.1158/1541-7786.MCR-13-0317.CrossRefPubMed

64.

Sapkota D, Costea DE, Blø M, Bruland O, Lorens JB, Vasstrand EN, et al. S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest. Oral Oncol. 2012;48(3):219–25. https://doi.org/10.1016/j.oraloncology.2011.10.001.CrossRefPubMed

65.

Xiong T-F, Pan F-Q, Li D. Expression and clinical significance of S100 family genes in patients with melanoma. Melanoma Res. 2019;29(1):23–9. https://doi.org/10.1097/CMR.0000000000000512.CrossRefPubMed

66.

Pagano M, Tam SW, Theodoras AM, Beer-Romero P, del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269(5224):682–5. https://doi.org/10.1126/science.7624798.CrossRefPubMed

67.

da Silva DC, Andrade PB, Ribeiro V, Valentao P, Pereira DM. Recent patents on proteasome inhibitors of natural origin. Recent Pat Anticancer Drug Discov. 2017;12(1):4–15. https://doi.org/10.2174/1574892812666161123142037.CrossRefPubMed

68.

Eichhorn T, Schloissnig S, Hahn B, Wendler A, Mertens R, Lehmann WD, et al. Bioinformatic and experimental fishing for artemisinin-interacting proteins from human nasopharyngeal cancer cells. Mol BioSyst. 2012;8(4):1311–8. https://doi.org/10.1039/c2mb05437j.CrossRefPubMed

69.

Efferth T. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. Semin Cancer Biol. 2017;46:65–83. https://doi.org/10.1016/j.semcancer.2017.02.009.CrossRefPubMed

70.

Zhang Y, Xu G, Zhang S, Wang D, Saravana Prabha P, Zuo Z. Antitumor research on artemisinin and its bioactive derivatives. Nat Products Bioprospect. 2018;8(4):303–19. https://doi.org/10.1007/s13659-018-0162-1.CrossRef

71.

Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquère S, Ripoche H, et al. Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to toll-like receptor 3-mediated apoptosis. Neoplasia. 2008;10(11):1183–94. https://doi.org/10.1593/neo.08590.CrossRefPubMedPubMedCentral

72.

Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009;113(11):2442–50. https://doi.org/10.1182/blood-2008-05-157222.CrossRefPubMedPubMedCentral

73.

Luo C, Wang J-J, Li Y-H, Hu J-Y, Li G-C. Immunogenicity and efficacy of a DNA vaccine encoding a human anti-idiotype single chain antibody against nasopharyngeal carcinoma. Vaccine. 2010;28(15):2769–74. https://doi.org/10.1016/j.vaccine.2010.01.033.CrossRefPubMed

74.

Bei J-X, Zuo X-Y, Liu W-S, Guo Y-M, Zeng Y-X. Genetic susceptibility to the endemic form of NPC. Chinese Clin Oncol. 2016;5(2):15. https://doi.org/10.21037/cco.2016.03.11.CrossRef

75.

Hildesheim A, Wang C-P. Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: Rosetta stone for NPC: genetics, viral infection, and other environmental factors. Semin Cancer Biol. 2012;22(2):107–16. https://doi.org/10.1016/j.semcancer.2012.01.007.CrossRefPubMedPubMedCentral

76.

Wang M, Kaufman RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature. 2016;529(7586):326–35. https://doi.org/10.1038/nature17041.CrossRefPubMed

77.

Hetz C, Papa FR. The unfolded protein response and cell fate control. Mol Cell. 2018;69(2):169–81. https://doi.org/10.1016/j.molcel.2017.06.017.CrossRefPubMed

78.

Adams CJ, Kopp MC, Larburu N, Nowak PR, Ali MMU. Structure and molecular mechanism of ER stress signaling by the unfolded protein response signal activator IRE1. Front Mol Biosci. 2019;6:11. https://doi.org/10.3389/fmolb.2019.00011.CrossRefPubMedPubMedCentral

79.

Zheng H, Dai W, Cheung AKL, Ko JMY, Kan R, Wong BWY, et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2016;113(40):11283–8. https://doi.org/10.1073/pnas.1607606113.CrossRefPubMedPubMedCentral

80.

Deng M, Dai W, Yu VZ, Tao L, Lung ML. Cylindromatosis lysine 63 deubiquitinase (CYLD) regulates NF-kB signaling pathway and modulates fibroblast and endothelial cells recruitment in nasopharyngeal carcinoma. Cancers (Basel). 2020;12(7). https://doi.org/10.3390/cancers12071924.

81.

Eluard B, Thieblemont C, Baud V. NF-κB in the new era of Cancer therapy. Trends Cancer. 2020;6(8):677–87. https://doi.org/10.1016/j.trecan.2020.04.003.CrossRefPubMed

82.

Liu Z, Luo W, Zhou Y, Zhen Y, Yang H, Yu X, et al. Potential tumor suppressor NESG1 as an unfavorable prognosis factor in nasopharyngeal carcinoma. PLoS One. 2011;6(11):e27887. https://doi.org/10.1371/journal.pone.0027887.CrossRefPubMedPubMedCentral

83.

Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, et al. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of southern China. J Transl Med. 2008;6(1):32. https://doi.org/10.1186/1479-5876-6-32.CrossRefPubMedPubMedCentral

84.

Liu Z, Chen C, Yang H, Zhang Y, Long J, Long X, et al. Proteomic features of potential tumor suppressor NESG1 in nasopharyngeal carcinoma. Proteomics. 2012;12(22):3416–25. https://doi.org/10.1002/pmic.201200146.CrossRefPubMed

85.

Cheng C, Li W, Peng X, et al. miR-1254 induced by NESG1 inactivates HDGF/DDX5-stimulated nuclear translocation of β-catenin and suppresses NPC metastasis. Mol Ther Methods Clin Dev. 2021;20:615–24. https://doi.org/10.1016/j.omtm.2021.02.001.CrossRefPubMedPubMedCentral

86.

Liang Z, Liu Z, Cheng C, Wang H, Deng X, Liu J, et al. VPS33B interacts with NESG1 to modulate EGFR/PI3K/AKT/c-Myc/P53/miR-133a-3p signaling and induce 5-fluorouracil sensitivity in nasopharyngeal carcinoma. Cell Death Dis. 2019;10(4):305. https://doi.org/10.1038/s41419-019-1457-9.CrossRefPubMedPubMedCentral

87.

Chen SH, Kuo CC, Li CF, Cheung CHA, Tsou TC, Chiang HC, et al. O(6) -methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma. Int J Cancer. 2015;137(6):1291–305. https://doi.org/10.1002/ijc.29486.CrossRefPubMed

88.

Feng J, Lu S-S, Xiao T, Huang W, Yi H, Zhu W, et al. ANXA1 binds and stabilizes EphA2 to promote nasopharyngeal carcinoma growth and metastasis. Cancer Res. 2020;80(20):4386–98. https://doi.org/10.1158/0008-5472.CAN-20-0560.CrossRefPubMed

89.

Wang L, Fan M, Zeng C, Li W, Hu Q, Liu W, et al. Expression and purification of a rapidly degraded protein, TMEM8B-a, in mammalian cell line. Protein Expr Purif. 2018;151:38–45. https://doi.org/10.1016/j.pep.2018.06.002.CrossRefPubMed

90.

Zeng R, Tan G, Li W, Ma Y. Increased expression of Cullin 3 in nasopharyngeal carcinoma and knockdown inhibits proliferation and invasion. Oncol Res. 2018;26(1):111–22. https://doi.org/10.3727/096504017X14924753593574.CrossRefPubMedPubMedCentral

91.

Chin Y-M, Mushiroda T, Takahashi A, Kubo M, Krishnan G, Yap LF, et al. HLA-A SNPs and amino acid variants are associated with nasopharyngeal carcinoma in Malaysian Chinese. Int J Cancer. 2015;136(3):678–87. https://doi.org/10.1002/ijc.29035.CrossRefPubMed

92.

Roy Chattopadhyay N, Chakrabarti S, Chatterjee K, Deb Roy S, Kumar Sahu S, Reddy RR, et al. Histocompatibility locus antigens regions contribute to the ethnicity bias of Epstein-Barr virus-associated nasopharyngeal carcinoma in higher-incidence populations. Scand J Immunol. 2019;90(4):e12796. https://doi.org/10.1111/sji.12796.CrossRefPubMed

93.

Douik H, Romdhane NA, Guemira F. Are HLA-E*0103 alleles predictive markers for nasopharyngeal cancer risk? Pathol Res Pract. 2016;212(4):345–9. https://doi.org/10.1016/j.prp.2016.01.010.CrossRefPubMed

94.

Sousa H, Mesquita L, Ribeiro J, Catarino R, Breda E, Medeiros R. Polymorphisms in host immune response associated genes and risk of nasopharyngeal carcinoma development in Portugal. Immunobiology. 2016;221(2):145–52. https://doi.org/10.1016/j.imbio.2015.09.015.CrossRefPubMed

95.

Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res. 2015;75(1):5–10. https://doi.org/10.1158/0008-5472.CAN-14-2538.CrossRefPubMed

96.

Seya T, Azuma M, Matsumoto M. Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer. Expert Opin Ther Targets. 2013;17(5):533–44. https://doi.org/10.1517/14728222.2013.765407.CrossRefPubMed

97.

Wu Y, Wu X, Wu L, Wang X, Liu Z. The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy. Transl Res. 2017;190:51–60. https://doi.org/10.1016/j.trsl.2017.08.004.CrossRefPubMed

98.

Xu X-X, Wan H, Nie L, Shao T, Xiang L-X, Shao J-Z. RIG-I: a multifunctional protein beyond a pattern recognition receptor. Protein Cell. 2018;9(3):246–53. https://doi.org/10.1007/s13238-017-0431-5.CrossRefPubMed

99.

Ma H, Jin S, Yang W, Zhou G, Zhao M, Fang S, et al. Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma. Br J Cancer. 2018;118(4):509–21. https://doi.org/10.1038/bjc.2017.442.CrossRefPubMedPubMedCentral

100.

Chen W, Han C, Xie B, Hu X, Yu Q, Shi L, et al. Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. Cell. 2013;152(3):467–78. https://doi.org/10.1016/j.cell.2013.01.011.CrossRefPubMed

101.

Zhao C, Jia M, Song H, Yu Z, Wang W, Li Q, et al. The E3 ubiquitin ligase TRIM40 attenuates antiviral immune responses by targeting MDA5 and RIG-I. Cell Rep. 2017;21(6):1613–23. https://doi.org/10.1016/j.celrep.2017.10.020.CrossRefPubMed

102.

Zhang H-L, Ye H-Q, Liu S-Q, et al. West nile virus NS1 antagonizes interferon beta production by targeting RIG-I and MDA5. J Virol. 2017;91(18). https://doi.org/10.1128/JVI.02396-16.

103.

Samanta M, Iwakiri D, Takada K. Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. Oncogene. 2008;27(30):4150–60. https://doi.org/10.1038/onc.2008.75.CrossRefPubMed

104.

Satoh T, Wada R, Yajima N, Imaizumi T, Yagihashi S. Tumor microenvironment and RIG-I signaling molecules in Epstein Barr virus-positive and -negative classical Hodgkin lymphoma of the elderly. J Clin Exp Hematop. 2014;54(1):75–84. https://doi.org/10.3960/jslrt.54.75.CrossRefPubMed

105.

Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147–54. https://doi.org/10.1172/JCI31178.CrossRefPubMedPubMedCentral

106.

Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2001;7(5):1419–28.

107.

Chon SY, Hassanain HH, Gupta SL. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem. 1996;271(29):17247–52. https://doi.org/10.1074/jbc.271.29.17247.CrossRefPubMed

108.

Zhu Q, Cai M-Y, Chen C-L, Hu H, Lin HX, Li M, et al. Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. Oncoimmunology. 2017;6(5):e1312240. https://doi.org/10.1080/2162402X.2017.1312240.CrossRefPubMedPubMedCentral

109.

Larbcharoensub N, Mahaprom K, Jiarpinitnun C, Trachu N, Tubthong N, Pattaranutaporn P, et al. Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in Epstein-Barr virus-associated nasopharyngeal carcinoma. Am J Clin Oncol. 2018;41(12):1204–10. https://doi.org/10.1097/COC.0000000000000449.CrossRefPubMed

110.

Ono T, Azuma K, Kawahara A, Sasada T, Matsuo N, Kakuma T, et al. Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment. Head Neck. 2018;40(9):2007–19. https://doi.org/10.1002/hed.25189.CrossRefPubMed

111.

Wang Y-Q, Chen Y-P, Zhang Y, Jiang W, Liu N, Yun JP, et al. Prognostic significance of tumor-infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: a large-scale cohort study. Int J Cancer. 2018;142(12):2558–66. https://doi.org/10.1002/ijc.31279.CrossRefPubMed

112.

Fang W, Zhang J, Hong S, et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget. 2014;5(23):12189–202. https://doi.org/10.18632/oncotarget.2608.CrossRefPubMedPubMedCentral

113.

Hsu C, Lee S-H, Ejadi S, Even C, Cohen RB, le Tourneau C, et al. Safety and antitumor activity of Pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(36):4050–6. https://doi.org/10.1200/JCO.2017.73.3675.CrossRef

114.

Ma BBY, Lim W-T, Goh B-C, Hui EP, Lo KW, Pettinger A, et al. Antitumor activity of Nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic phase 2 consortium (NCI-9742). J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(14):1412–8. https://doi.org/10.1200/JCO.2017.77.0388.CrossRef

115.

Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19(10):1338–50. https://doi.org/10.1016/S1470-2045(18)30495-9.CrossRefPubMed

116.

Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet (London, England). 2019;394(10192):64–80. https://doi.org/10.1016/S0140-6736(19)30956-0.CrossRef

117.

Buac D, Shen M, Schmitt S, Rani Kona F, Deshmukh R, Zhang Z, et al. From bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des. 2013;19(22):4025–38. https://doi.org/10.2174/1381612811319220012.CrossRefPubMedPubMedCentral

118.

Lynce F, Wang H, Petricoin EF, Pohlmann PR, Smaglo B, Hwang J, et al. A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. Cancer Chemother Pharmacol. 2019;84(5):1145–51. https://doi.org/10.1007/s00280-019-03947-7.CrossRefPubMedPubMedCentral

119.

Rowinsky EK, Paner A, Berdeja JG, Paba-Prada C, Venugopal P, Porkka K, et al. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Investig New Drugs. 2020;38(5):1448–53. https://doi.org/10.1007/s10637-020-00915-4.CrossRef

120.

Lara PNJ, Chansky K, Davies AM, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a southwest oncology group phase II trial (S0327). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2006;1(9):996–1001.

121.

Drilon A, Schoenfeld AJ, Arbour KC, et al. Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Cold Spring Harb Mol Case Stud. 2019;5(2). https://doi.org/10.1101/mcs.a003665.

122.

Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, et al. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: north central Cancer treatment group (NCCTG)-N0321. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10(1):172–80. https://doi.org/10.1097/JTO.0000000000000383.CrossRef

123.

Kim DW, Shyr Y, Shaktour B, Akerley W, Johnson DH, Choy H. Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer. 2005;50(2):235–45. https://doi.org/10.1016/j.lungcan.2005.05.020.CrossRefPubMed

124.

Lara PNJ, Longmate J, Reckamp K, et al. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011;12(1):33–7. https://doi.org/10.3816/CLC.2011.n.004.CrossRefPubMedPubMedCentral

125.

Taromi S, Lewens F, Arsenic R, et al. Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer. Oncotarget. 2017;8(57):97061–78. https://doi.org/10.18632/oncotarget.21221.CrossRefPubMedPubMedCentral

126.

Gilbert J, Lee JW, Argiris A, Haigentz M Jr, Feldman LE, Jang M, et al. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of. Head Neck. 2013;35(7):942–8. https://doi.org/10.1002/hed.23046.CrossRefPubMed

127.

Soriano GP, Besse L, Li N, Kraus M, Besse A, Meeuwenoord N, et al. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia. 2016;30(11):2198–207. https://doi.org/10.1038/leu.2016.102.CrossRefPubMedPubMedCentral

128.

Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-Plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2015;28(4):541–2. https://doi.org/10.1016/j.ccell.2015.09.010.CrossRefPubMed

129.

Zang M, Guo J, Liu L, Jin F, Feng X, An G, et al. Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s. Oncogenesis. 2020;9(3):31. https://doi.org/10.1038/s41389-020-0216-1.CrossRefPubMedPubMedCentral

130.

Dytfeld D, Luczak M, Wrobel T, et al. Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget. 2016;7(35):56726–36. https://doi.org/10.18632/oncotarget.11059.CrossRefPubMedPubMedCentral

131.

Ferrington DA, Gregerson DS. Immunoproteasomes: structure, function, and antigen presentation. Prog Mol Biol Transl Sci. 2012;109:75–112. https://doi.org/10.1016/B978-0-12-397863-9.00003-1.CrossRefPubMedPubMedCentral

132.

Basler M, Mundt S, Bitzer A, Schmidt C, Groettrup M. The immunoproteasome: a novel drug target for autoimmune diseases. Clin Exp Rheumatol. 2015;33(4 Suppl 92):S74–9.PubMed

133.

van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019;7(1):263. https://doi.org/10.1186/s40425-019-0761-3.CrossRefPubMedPubMedCentral

134.

de LA Santos R, Bai L, Singh PK, et al. Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes. Nat Commun. 2017;8(1):1692. https://doi.org/10.1038/s41467-017-01760-5.CrossRefPubMedPubMedCentral

135.

Sosič I, Gobec M, Brus B, Knez D, Živec M, Konc J, et al. Nonpeptidic selective inhibitors of the chymotrypsin-like (β5 i) subunit of the immunoproteasome. Angew Chem Int Ed Engl. 2016;55(19):5745–8. https://doi.org/10.1002/anie.201600190.CrossRefPubMed

136.

Cui H, Baur R, Le Chapelain C, et al. Structural elucidation of a Nonpeptidic inhibitor specific for the human immunoproteasome. Chembiochem. 2017;18(6):523–6. https://doi.org/10.1002/cbic.201700021.CrossRefPubMed

137.

Tsvetkov P, Detappe A, Cai K, Keys HR, Brune Z, Ying W, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019;15(7):681–9. https://doi.org/10.1038/s41589-019-0291-9.CrossRefPubMedPubMedCentral

138.

Ge M, Qiao Z, Kong Y, Lu H, Liu H. Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia. Cancer Sci. 2020;111(4):1279–90. https://doi.org/10.1111/cas.14351.CrossRefPubMedPubMedCentral

139.

Cohen P, Tcherpakov M. Will the ubiquitin system furnish as many drug targets as protein kinases? Cell. 2010;143(5):686–93. https://doi.org/10.1016/j.cell.2010.11.016.CrossRefPubMed

140.

Banerjee S, Bartesaghi A, Merk A, Rao P, Bulfer SL, Yan Y, et al. 2.3 Å resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition. Science. 2016;351(6275):871–5. https://doi.org/10.1126/science.aad7974.CrossRefPubMedPubMedCentral

141.

Bastola P, Neums L, Schoenen FJ, Chien J. VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal. Mol Oncol. 2016;10(10):1559–74. https://doi.org/10.1016/j.molonc.2016.09.005.CrossRefPubMedPubMedCentral

142.

Crews CM. Targeting the undruggable proteome: the small molecules of my dreams. Chem Biol. 2010;17(6):551–5. https://doi.org/10.1016/j.chembiol.2010.05.011.CrossRefPubMedPubMedCentral

143.

Chen X, Dou QP, Liu J, Tang D. Targeting ubiquitin-proteasome system with copper complexes for Cancer therapy. Front Mol Biosci. 2021;8:649151. https://doi.org/10.3389/fmolb.2021.649151.CrossRefPubMedPubMedCentral

144.

Milardi D, Arnesano F, Grasso G, Magrì A, Tabbì G, Scintilla S, et al. Ubiquitin stability and the Lys63-linked polyubiquitination site are compromised on copper binding. Angew Chem Int Ed Engl. 2007;46(42):7993–5. https://doi.org/10.1002/anie.200701987.CrossRefPubMed

145.

Arnesano F, Scintilla S, Calò V, Bonfrate E, Ingrosso C, Losacco M, et al. Copper-triggered aggregation of ubiquitin. PLoS One. 2009;4(9):e7052. https://doi.org/10.1371/journal.pone.0007052.CrossRefPubMedPubMedCentral

146.

Santoro AM, Monaco I, Attanasio F, Lanza V, Pappalardo G, Tomasello MF, et al. Copper(II) ions affect the gating dynamics of the 20S proteasome: a molecular and in cell study. Sci Rep. 2016;6(1):33444. https://doi.org/10.1038/srep33444.CrossRefPubMedPubMedCentral

147.

Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017;552(7684):194–9. https://doi.org/10.1038/nature25016.CrossRefPubMedPubMedCentral

148.

Sharma A, Goyal AK, Rath G. Recent advances in metal nanoparticles in cancer therapy. J Drug Target. 2018;26(8):617–32. https://doi.org/10.1080/1061186X.2017.1400553.CrossRefPubMed

149.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. https://doi.org/10.1056/NEJMoa1501824.CrossRefPubMed

150.

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–30. https://doi.org/10.1056/NEJMoa2002788.CrossRefPubMed

151.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. https://doi.org/10.1056/NEJMoa1712126.CrossRefPubMedPubMedCentral

152.

Ferris RL, Blumenschein GJ, Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45–51. https://doi.org/10.1016/j.oraloncology.2018.04.008.CrossRefPubMedPubMedCentral

153.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46. https://doi.org/10.1056/NEJMoa1910836.CrossRefPubMed

154.

Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373–9. https://doi.org/10.1111/cas.13027.CrossRefPubMedPubMedCentral

155.

Thirukkumaran CM, Shi ZQ, Nuovo GJ, Luider J, Kopciuk KA, Dong Y, et al. Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. Blood Adv. 2019;3(5):797–812. https://doi.org/10.1182/bloodadvances.2018025593.CrossRefPubMedPubMedCentral

156.

Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(35):8942–9. https://doi.org/10.1200/JCO.2005.02.6195.CrossRef

Title: Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer
Authors: Ramon Yarza
Mateo Bover
Maria Teresa Agulló-Ortuño
Lara Carmen Iglesias-Docampo
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Epstein-Barr Virus
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-02010-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Retraction Note: TGF-β2 initiates autophagy via Smad and non-Smad pathway to promote glioma cells’ invasion

DISE/6mer seed toxicity-a powerful anti-cancer mechanism with implications for other diseases

Hsa_circ_0005273 facilitates breast cancer tumorigenesis by regulating YAP1-hippo signaling pathway

Dendrimer-modified gold nanorods as a platform for combinational gene therapy and photothermal therapy of tumors

Exosomal miR-106b-5p derived from melanoma cell promotes primary melanocytes epithelial-mesenchymal transition through targeting EphA4

Cell surface GRP78 regulates BACE2 via lysosome-dependent manner to maintain mesenchymal phenotype of glioma stem cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer